(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 January 2009 (22.01.2009)

PCT

(10) International Publication Number
WO 2009/009881 A1

(51) International Patent Classification:
C07K 16/30 (2006.01) *C07K 16/46* (2006.01)
A61K 39/395 (2006.01) *C07K 19/00* (2006.01)
A61K 47/48 (2006.01) *C12N 5/16* (2006.01)
A61K 51/10 (2006.01) *C12P 21/08* (2006.01)
A61P 35/00 (2006.01) *G01N 33/574* (2006.01)
A61P 37/04 (2006.01) *G01N 33/577* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/CA2008/001288

(22) International Filing Date: 14 July 2008 (14.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/949,947 16 July 2007 (16.07.2007) US

(71) Applicant *(for all designated States except US)*: **ARIUS RESEARCH INC.** [CA/CA]; 55 York Street, 15th Floor, Toronto, Ontario M5J 1R7 (CA).

(72) Inventors: **YOUNG, David, S. F.**; 33 University Avenue, Suite 2407, Toronto, Ontario M5J 2S7 (CA). **FINDLAY, Helen, P.**; 205 Glendonwynne Road, Toronto, Ontario M6P 3E9 (CA). **HAHN, Susan, E.**; 9 Innisfree Court, Toronto, Ontario M6S 3N7 (CA). **CECHETTO, Lisa, M.**; Unit 303 of JSD Ville II, 653-31 Hannam-dong, Yongsan-gu, Seoul 140-210, South Korea (KR).

(74) Agent: **SINGLEHURST, John, C.**; Finlayson & Singlehurst, 70 Gloucester Street, Ottawa, ON K2P 0A2 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,

[Continued on next page]

(54) Title: AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY

FIGURE 4



(57) Abstract: Antibody mediated killing of cancer cells is an effective approach to treat cancer Antibodies generated in mice, upon immunization with ovarian cancer cells, are screened for cytotoxicity against a variety of cancer cell lines as the endpomt An anti-cancer cytotoxic monoclonal antibody is isolated, produced by the hybπdoma AR104A1289 2 2 deposited with IDAC as Accession Number 190607-04, which is cytotoxic to a colon cancer cell line, and reduces tumor burden in animal models of human pancreatic, breast and prostate cancer The monoclonal antibody also binds to several cancer cell lines The monoclonal antibody does not cause cytotoxicity to a non-cancer cell line, though it binds the cell line This monoclonal antibody can be used to aid staging and diagnosis of cancer, and in the treatment of primary tumors and tumor metastases This cytotoxic monoclonal antibody can also be used to deliver toxms, enzymes, radioactive compounds and hematogenous cells to cancer cells, to further aid reduction of tumor burden.

WO 2009/009881 A1

NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report*